These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 28953345)

  • 1. Outcomes-Based Pharmaceutical Contracts: An Answer to High U.S. Drug Spending?
    Seeley E; Kesselheim AS
    Issue Brief (Commonw Fund); 2017 Sep; 2017():1-8. PubMed ID: 28953345
    [TBL] [Abstract][Full Text] [Related]  

  • 2. AMCP Guide to Pharmaceutical Payment Methods, 2009 Update (Version 2.0).
    Academy of Managed Care Pharmacy
    J Manag Care Pharm; 2009 Aug; 15(6 Suppl A):S3-57, quiz S58-61. PubMed ID: 19678720
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The High Cost of Prescription Drugs in the United States: Origins and Prospects for Reform.
    Kesselheim AS; Avorn J; Sarpatwari A
    JAMA; 2016 Aug 23-30; 316(8):858-71. PubMed ID: 27552619
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Canadian policy makers' views on pharmaceutical reimbursement contracts involving confidential discounts from drug manufacturers.
    Morgan SG; Thomson PA; Daw JR; Friesen MK
    Health Policy; 2013 Oct; 112(3):248-54. PubMed ID: 23809914
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The pharmacist's role in shaping the future of value-based payment models in state Medicaid programs.
    Cothran T; Holderread B; Abbott M; Nesser N; Keast S
    J Am Pharm Assoc (2003); 2019; 59(1):121-124. PubMed ID: 30528252
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of U.S. federal and state generic drug policies on drug use, spending, and patient outcomes: A systematic review.
    Mishuk AU; Fasina I; Qian J
    Res Social Adm Pharm; 2020 Jun; 16(6):736-745. PubMed ID: 31445986
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Review of US Drug Costs Relevant to Medicare, Medicaid, and Commercial Insurers Post-Affordable Care Act Enactment, 2010-2016.
    McRae J; Vogenberg FR; Beaty SW; Mearns E; Varga S; Pizzi L
    Pharmacoeconomics; 2017 Feb; 35(2):215-223. PubMed ID: 27798809
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Value-Based Pharmaceutical Contracts: Value for Whom?
    Kannarkat JT; Good CB; Parekh N
    Value Health; 2020 Feb; 23(2):154-156. PubMed ID: 32113619
    [TBL] [Abstract][Full Text] [Related]  

  • 9. AMCP Guide to Pharmaceutical Payment Methods.
    AMCP Task Force on Drug Payment Methodologies
    J Manag Care Pharm; 2007 Oct; 13(8 Suppl C):S1-39. PubMed ID: 17970611
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlation Between Changes in Brand-Name Drug Prices and Patient Out-of-Pocket Costs.
    Rome BN; Feldman WB; Desai RJ; Kesselheim AS
    JAMA Netw Open; 2021 May; 4(5):e218816. PubMed ID: 33944925
    [TBL] [Abstract][Full Text] [Related]  

  • 11. National health spending in 2011: overall growth remains low, but some payers and services show signs of acceleration.
    Hartman M; Martin AB; Benson J; Catlin A;
    Health Aff (Millwood); 2013 Jan; 32(1):87-99. PubMed ID: 23297275
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Estimates of Medicaid and Non-Medicaid Net Prices of Top-Selling Brand-name Drugs Incorporating Best Price Rebates, 2015 to 2019.
    Clemans-Cope L; Epstein M; Banthin J; Kesselheim AS; Hwang TJ
    JAMA Health Forum; 2023 Jan; 4(1):e225012. PubMed ID: 36637815
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Current Status of Outcomes-Based Contracting for Manufacturers and Payers: An AMCP Membership Survey.
    Duhig AM; Saha S; Smith S; Kaufman S; Hughes J
    J Manag Care Spec Pharm; 2018 May; 24(5):410-415. PubMed ID: 29337604
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Has The Era Of Slow Growth For Prescription Drug Spending Ended?
    Aitken M; Berndt ER; Cutler D; Kleinrock M; Maini L
    Health Aff (Millwood); 2016 Sep; 35(9):1595-603. PubMed ID: 27605638
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Business of Health. Business of Healthcare.
    Berry MD;
    Issue Brief Health Policy Track Serv; 2018 Dec; 2018():1-60. PubMed ID: 30681304
    [No Abstract]   [Full Text] [Related]  

  • 16. Factors associated with independent pharmacy owners' satisfaction with Medicare Part D contracts.
    Zhang S; Doucette WR; Urmie JM; Xie Y; Brooks JM
    Res Social Adm Pharm; 2010 Jun; 6(2):121-9. PubMed ID: 20511111
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmaceuticals and medical devices: Medicare Part D. End-of-year issue brief.
    Chaps NA
    Issue Brief Health Policy Track Serv; 2009 Jan; ():1-26. PubMed ID: 19301435
    [No Abstract]   [Full Text] [Related]  

  • 18. Getting to the Root of High Prescription Drug Prices.
    Waxman H; Corr B; Martin K; Duong S
    Issue Brief (Commonw Fund); 2017 Jul; 2017():1-10. PubMed ID: 28700190
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Net Spending On Retail Specialty Drugs Grew Rapidly, Especially For Private Insurance And Medicare Part D.
    Hill SC; Miller GE; Ding Y
    Health Aff (Millwood); 2020 Nov; 39(11):1970-1976. PubMed ID: 33136501
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Does bargaining affect Medicare prescription drug plan reimbursements to independent pharmacies?
    Tang Y; Xie Y; Urmie JM; Doucette WR
    J Am Pharm Assoc (2003); 2011; 51(6):738-45. PubMed ID: 22068196
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.